Literature DB >> 23883603

The clinical dilemma of "silent desensitization" in aspirin-exacerbated respiratory disease.

Andrew A White1, John V Bosso, Donald D Stevenson.   

Abstract

Aspirin desensitization is a treatment option for patients with aspirin-exacerbated respiratory disease (AERD). Some patients with an excellent history of aspirin or nonsteroidal anti-inflammatory drug (NSAID) reactions have negative aspirin challenges/desensitization. This study discusses the clinical entity of silent desensitization in AERD and the dilemma that this presents to the practicing allergist/immunologist. We discuss a series of patients with a strong history of NSAID reactions who initially underwent a negative challenge/silent desensitization. These patients were subsequently proven to have AERD after a second positive aspirin challenge. Silent desensitization is an uncommon but important outcome to recognize in AERD. Clinicians performing aspirin desensitization should understand that this can occur and consider a second confirmatory aspirin challenge in some patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23883603     DOI: 10.2500/aap.2013.34.3670

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  9 in total

Review 1.  Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).

Authors:  Ronald A Simon; Kristen M Dazy; Jeremy D Waldram
Journal:  Curr Allergy Asthma Rep       Date:  2015-03       Impact factor: 4.806

2.  Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease.

Authors:  Kathleen Lee-Sarwar; Christina Johns; Tanya M Laidlaw; Katherine N Cahill
Journal:  J Allergy Clin Immunol Pract       Date:  2015-01-26

Review 3.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

4.  Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database.

Authors:  Lauren T Roland; Heqiong Wang; C Christina Mehta; Katherine N Cahill; Tanya M Laidlaw; John M DelGaudio; Sarah K Wise; Joshua M Levy
Journal:  Int Forum Allergy Rhinol       Date:  2019-08-23       Impact factor: 3.858

Review 5.  Update on Aspirin-Exacerbated Respiratory Disease.

Authors:  Katharine M Woessner
Journal:  Curr Allergy Asthma Rep       Date:  2017-01       Impact factor: 4.806

6.  Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease.

Authors:  Elina Jerschow; Matthew L Edin; Yuling Chi; Beth Hurst; Waleed M Abuzeid; Nadeem A Akbar; Marc Gibber; Marvin P Fried; Weiguo Han; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; Fred B Lih; Artiom Gruzdev; J Alyce Bradbury; Victor Schuster; Simon Spivack; David Rosenstreich; Darryl C Zeldin
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-21

7.  Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.

Authors:  Whitney W Stevens; Anju T Peters; Annemarie G Hirsch; Cara M Nordberg; Brian S Schwartz; Dione G Mercer; Mahboobeh Mahdavinia; Leslie C Grammer; Kathryn E Hulse; Robert C Kern; Pedro Avila; Robert P Schleimer
Journal:  J Allergy Clin Immunol Pract       Date:  2017-03-09

Review 8.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

9.  Artificial neural network identifies nonsteroidal anti-inflammatory drugs exacerbated respiratory disease (N-ERD) cohort.

Authors:  Katarzyna Ewa Tyrak; Kinga Pajdzik; Ewa Konduracka; Adam Ćmiel; Bogdan Jakieła; Natalia Celejewska-Wójcik; Gabriela Trąd; Adrianna Kot; Anna Urbańska; Ewa Zabiegło; Radosław Kacorzyk; Izabela Kupryś-Lipińska; Krzysztof Oleś; Piotr Kuna; Marek Sanak; Lucyna Mastalerz
Journal:  Allergy       Date:  2020-03-03       Impact factor: 13.146

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.